Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib + SHR6390 + endocrine therapy in HR+/HER2- advanced breast cancer
ChiCTR2100053950Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famitinib and dalpiciclib in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoints: Recommended phase II dose and Objective response rate. Started Dec 2021; status: recruiting.
02
Drugs
famitinibdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100053950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053950.